Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunocore Holdings (IMCR)
NASDAQ:IMCR
Holding IMCR?
Track your performance easily
IMCR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$32.37 - $76.98
Previous Close$33.9
Volume394.11K
Average Volume (3M)474.21K
Market Cap
$1.70B
Enterprise Value$1.35B
Total Cash (Recent Filing)£332.54M
Total Debt (Recent Filing)£69.30M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 06, 2024EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding48,088,346
10 Day Avg. Volume487,427
30 Day Avg. Volume474,211
Standard Deviation0.16
R-Squared0.05
Alpha-0.00283
Financial Highlights & Ratios
Price to Book (P/B)4.54
Price to Sales (P/S)8.29
Price to Cash Flow (P/CF)32.70
P/FCF Ratio23.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$81.33Price Target Upside136.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Immunocore Holdings News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyBrenetafusp shows early signs of efficacy in heavily pre-treated platinum-resistant ovarian cancer patients.
Combination TherapyThe addition of chemotherapy to brenetafusp saw an improvement in activity with increases seen in ORR, DCR, and molecular response.
Market PerformanceKimmtrak sales of $75.4 million beat consensus estimates, showing growth across the US and Rest of the World.
Bears Say
Investor SentimentGiven the negative investor sentiment surrounding brenetafusp after the ASCO melanoma data, expectations are quite low into this readout.
Reimbursement EnvironmentThe outlook in Europe is less positive, with the company citing a highly challenging reimbursement environment which could pose a risk to indication expansion in the region.
Stock PerformanceIMCR stock is in a pullback phase given ASCO data in June showed interesting and promising data for PRAME in 2L+ melanoma but underwhelmed Street expectations.
---
Ownership Overview
0.04% Insiders
26.51% Mutual Funds
44.41% Other Institutional Investors
29.04% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMCR FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was $32.37 and its highest was $76.98 in the past 12 months.
What is Immunocore Holdings’s market cap?
Currently, no data Available
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on Aug 08, 2024. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.476 by $0.246.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is -$0.37.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 50,018,757 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.476. Following the earnings report the stock price went up 2.764%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Among the largest hedge funds holding Immunocore Holdings’s share is PRIMECAP Management Co. It holds Immunocore Holdings’s shares valued at 66M.
---
Immunocore Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.33 (136.15% Upside)
$81.33 (136.15% Upside)
Blogger Sentiment
Bullish
IMCR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 23.7%
Last 30 Days ▲ 19.7%
Last 30 Days ▲ 19.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.78%
12-Months-Change
Fundamentals
Return on Equity
-15.05%
Trailing 12-Months
Asset Growth
82.79%
Trailing 12-Months
Company Description
Immunocore Holdings
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases.
---
IMCR Company Deck
---
IMCR Earnings Call
Q2 2024
0:00 / 0:00
---
IMCR Stock 12 Month Forecast
Average Price Target
$81.33
▲(136.15% Upside)
Technical Analysis
Best Analysts Covering IMCR
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
-4.93%
reiterated a buy rating 3 days ago
Copying Justin Kim's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of -4.93% per trade.
---